4 results match your criteria: "Roseman University of Health Sciences College of Medicine[Affiliation]"
Lecanemab (BAN2401): an anti-beta-amyloid monoclonal antibody for the treatment of Alzheimer disease.
Expert Opin Investig Drugs
February 2023
Department of Neurology, Barrow Neurological Institute, St. Joseph's Hospital and Medical Center, Phoenix, Arizona.
Article Synopsis
- - Nearly a dozen monoclonal antibodies (mAbs) targeting beta-amyloid (Aβ) are in development for Alzheimer's disease, with lecanemab showing promise in clinical trials by specifically targeting large Aβ protofibrils.
- - Phase 2 trials of lecanemab indicated effective results and manageable risks for amyloid-related imaging abnormalities (ARIAs), leading to its further study in phase 3 trials.
- - The development of Aβ-targeting mAbs is critical for Alzheimer's treatment, with lessons learned from other mAbs like aducanumab, emphasizing the need to target specific Aβ forms for better efficacy and safety monitoring for ARIAs.
Expectations of and for Clerkship Directors 2.0: A Collaborative Statement from the Alliance for Clinical Education.
Teach Learn Med
October 2021
Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
This article presents an update of the collaborative statement on clerkship directors (CDs), first published in 2003, from the national undergraduate medical education organizations that comprise the Alliance for Clinical Education (ACE). The clerkship director remains an essential leader in the education of medical students on core clinical rotations, and the role of the CD has and continues to evolve. The selection of a CD should be an explicit contract between the CD, their department, and the medical school, with each party fulfilling their obligations to ensure the success of the students, the clerkship and of the CD.
View Article and Find Full Text PDFLessons from next generation influenza vaccines for inflammatory disease therapies.
Int Immunopharmacol
September 2019
Roseman University of Health Sciences College of Medicine, 10530 Discovery Dr., Las Vegas, NV 89135, USA. Electronic address:
Lessons can be learned for treating inflammatory diseases such as rheumatoid arthritis (RA) from next generation approaches for development of universal influenza vaccines. Immunomodulation of inflammatory diseases, rather than ablation of cytokine or cellular responses, can address the root cause of the disease and provide potential cure. Like influenza, there are different antigenic 'strains' and inflammatory T cell responses, Th1 or Th17, that drive each person's disease.
View Article and Find Full Text PDFAn epitope-specific DerG-PG70 LEAPS vaccine modulates T cell responses and suppresses arthritis progression in two related murine models of rheumatoid arthritis.
Vaccine
July 2017
CEL-SCI Corporation, 8229 Boone Blvd., Suite 802, Vienna, VA 22182, United States. Electronic address:
Rheumatoid arthritis (RA) is an autoimmune joint disease maintained by aberrant immune responses involving CD4+ T helper (Th)1 and Th17 cells. In this study, we tested the therapeutic efficacy of Ligand Epitope Antigen Presentation System (LEAPS™) vaccines in two Th1 cell-driven mouse models of RA, cartilage proteoglycan (PG)-induced arthritis (PGIA) and PG G1-domain-induced arthritis (GIA). The immunodominant PG peptide PG70 was attached to a DerG or J immune cell binding peptide, and the DerG-PG70 and J-PG70 LEAPS vaccines were administered to the mice after the onset of PGIA or GIA symptoms.
View Article and Find Full Text PDF